|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tevaarwerk AJ, Gray RJ, Schneider BP,
Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller
KD and Sparano JA: Survival in patients with metastatic recurrent
breast cancer after adjuvant chemotherapy: Little evidence of
improvement over the past 30 years. Cancer. 119:1140–1148. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang YL and Liu ZP: Natural products as
anti-invasive and anti-metastatic agents. Curr Med Chem.
18:808–829. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ci Y, Qiao J and Han M: Molecular
mechanisms and metabolomics of natural polyphenols interfering with
breast cancer metastasis. Molecules. 21:E16342016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borner C: The Bcl-2 protein family:
Sensors and checkpoints for life-or-death decisions. Mol Immunol.
39:615–647. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams JM and Cory S: Life-or-death
decisions by the Bcl-2 protein family. Trends Biochem Sci.
26:61–66. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Um HD: Bcl-2 family proteins as regulators
of cancer cell invasion and metastasis: A review focusing on
mitochondrial respiration and reactive oxygen species. Oncotarget.
7:5193–5203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wick W, Wagner S, Kerkau S, Dichgans J,
Tonn JC and Weller M: BCL-2 promotes migration and invasiveness of
human glioma cells. FEBS Lett. 440:419–424. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wick W, Wild-Bode C, Frank B and Weller M:
BCL-2-induced glioma cell invasiveness depends on furin-like
proteases. J Neurochem. 91:1275–1283. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Choi J, Choi K, Benveniste EN, Rho SB,
Hong YS, Lee JH, Kim J and Park K: Bcl-2 promotes invasion and lung
metastasis by inducing matrix metalloproteinase-2. Cancer Res.
65:5554–5560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Del Bufalo D, Biroccio A, Leonetti C and
Zupi G: Bcl-2 overexpression enhances the metastatic potential of a
human breast cancer line. FASEB J. 11:947–953. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
An J, Lv J, Li A, Qiao J, Fang L, Li Z, Li
B, Zhao W, Chen H and Wang L: Constitutive expression of Bcl-2
induces epithelial-Mesenchymal transition in mammary epithelial
cells. BMC Cancer. 15:4762015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang Y, Siegel PM, Shu W, Drobnjak M,
Kakonen SM, Cordón-Cardo C, Guise TA and Massagué J: A multigenic
program mediating breast cancer metastasis to bone. Cancer Cell.
3:537–549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pinkas J, Martin SS and Leder P:
Bcl-2-mediated cell survival promotes metastasis of EpH4 betaMEKDD
mammary epithelial cells. Mol Cancer Res. 2:551–556.
2004.PubMed/NCBI
|
|
16
|
Cang S, Iragavarapu C, Savooji J, Song Y
and Liu D: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical
development. J Hematol Oncol. 8:1292015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dawson SJ, Makretsov N, Blows FM, Driver
KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG,
McLean CA, et al: BCL2 in breast cancer: A favourable prognostic
marker across molecular subtypes and independent of adjuvant
therapy received. Br J Cancer. 103:668–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oakes SR, Vaillant F, Lim E, Lee L,
Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, et al:
Sensitization of BCL-2-expressing breast tumors to chemotherapy by
the BH3 mimetic ABT-737. Proc Natl Acad Sci USA. 109:2766–2771.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kerr DA II and Wittliff JL: A five-gene
model predicts clinical outcome in ER+/PR+, early-stage breast
cancers treated with adjuvant tamoxifen. Horm Cancer. 2:261–271.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choi JE, Kang SH, Lee SJ and Bae YK:
Prognostic significance of Bcl-2 expression in non-basal
triple-negative breast cancer patients treated with
anthracycline-based chemotherapy. Tumour Biol. 35:12255–12263.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neri A, Marrelli D, Roviello F, DeMarco G,
Mariani F, DeStefano A, Megha T, Caruso S, Corso G, Cioppa T and
Pinto E: Bcl-2 expression correlates with lymphovascular invasion
and long-term prognosis in breast cancer. Breast Cancer Res Treat.
99:77–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ishijima N, Miki C, Ishida T, Kinoshita T
and Suzuki H: The immunohistochemical expression of BCL-2
oncoprotein in colorectal adenocarcinoma. Surg Today. 29:682–684.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin D, Kuang G, Wan J, Zhang X and Li H,
Gong X and Li H: Luteolin suppresses the metastasis of
triple-negative breast cancer by reversing
epithelial-to-mesenchymal transition via downregulation of
β-catenin expression. Oncol Rep. 37:895–902. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hazan RB, Phillips GR, Qiao RF, Norton L
and Aaronson SA: Exogenous expression of N-cadherin in breast
cancer cells induces cell migration, invasion, and metastasis. J
Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun T, Sun BC, Zhao XL, Zhao N, Dong XY,
Che N, Yao Z, Ma YM, Gu Q, Zong WK and Liu ZY: Promotion of tumor
cell metastasis and vasculogenic mimicry by way of transcription
coactivation by Bcl-2 and Twist1: A study of hepatocellular
carcinoma. Hepatology. 54:1690–1706. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zuo J, Ishikawa T, Boutros S, Xiao Z,
Humtsoe JO and Kramer RH: Bcl-2 overexpression induces a partial
epithelial to mesenchymal transition and promotes squamous
carcinoma cell invasion and metastasis. Mol Cancer Res. 8:170–182.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu PJ, Lu QL, Rughetti A and
Taylor-Papadimitriou J: Bcl-2 overexpression inhibits cell death
and promotes the morphogenesis, but not tumorigenesis of human
mammary epithelial cells. J Cell Biol. 129:1363–1378. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang D, Sui M, Zhong W, Huang Y and Fan
W: Different administration strategies with paclitaxel induce
distinct phenotypes of multidrug resistance in breast cancer cells.
Cancer Lett. 335:404–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koehler BC, Scherr AL, Lorenz S, Urbanik
T, Kautz N, Elssner C, Welte S, Bermejo JL, Jäger D and
Schulze-Bergkamen H: Beyond cell death-antiapoptotic Bcl-2 proteins
regulate migration and invasion of colorectal cancer cells in
vitro. PLoS One. 8:e764462013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bonnefoy-Berard N, Aouacheria A,
Verschelde C, Quemeneur L, Marçais A and Marvel J: Control of
proliferation by Bcl-2 family members. Biochim Biophys Acta.
1644:159–168. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan R, Ruvolo VR, Wei J, Konopleva M, Reed
JC, Pellecchia M, Andreeff M and Ruvolo PP: Inhibition of Mcl-1
with the pan-Bcl-2 family inhibitor (−)BI97D6 overcomes ABT-737
resistance in acute myeloid leukemia. Blood. 126:363–372. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges
J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Jin S, Abraham V, Huang X, Liu B,
Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, et al: The
Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity
of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther.
10:2340–2349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Crawford A and Nahta R: Targeting Bcl-2 in
herceptin-resistant breast cancer cell lines. Curr Pharmacogenomics
Persona Med. 9:184–190. 2011. View Article : Google Scholar
|
|
36
|
Vaillant F, Merino D, Lee L, Breslin K,
Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ,
et al: Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen
receptor-positive breast cancer. Cancer Cell. 24:120–129. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deng J and Letai A: Priming BCL-2 to kill:
The combination therapy of tamoxifen and ABT-199 in ER+ breast
cancer. Breast Cancer Res. 15:3172013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li B, Chonghaile Ni T, Fan Y, Madden SF,
Klinger R, O'Connor AE, Walsh L, O'Hurley G, Udupi Mallya G, Joseph
J, et al: Therapeutic rationale to target highly expressed CDK7
conferring poor outcomes in triple-negative breast cancer. Cancer
Res. 77:3834–3845. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dukelow T, Kishan D, Khasraw M and Murphy
CG: CDK4/6 inhibitors in breast cancer. Anticancer Drugs.
26:797–806. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell
RG and Wu K: Recent advances of highly selective CDK4/6 inhibitors
in breast cancer. J Hematol Oncol. 10:972017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu J: Palbociclib: A first-in-class
CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive
advanced breast cancer. J Hematol Oncol. 8:982015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang P, Tong Z, Tian F, Wang Y, Yang J,
Li W, Di L, Liu W, Tang L, Qiu R and Xu B: Phase II trial of
utidelone as monotherapy or in combination with capecitabine in
heavily pretreated metastatic breast cancer patients. J Hematol
Oncol. 9:682016. View Article : Google Scholar : PubMed/NCBI
|
